|
Volumn 99, Issue 2, 2002, Pages 167-170
|
Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma
|
Author keywords
C reactive protein; Malignant fibrous histiocytoma; Paraneoplastic syndrome; Prognosis; Tumor marker
|
Indexed keywords
C REACTIVE PROTEIN;
CISPLATIN;
DACARBAZINE;
DOXORUBICIN;
IFOSFAMIDE;
TUMOR MARKER;
VINCRISTINE;
ADULT;
AGED;
ARTICLE;
CANCER ADJUVANT THERAPY;
CANCER RECURRENCE;
CLINICAL ARTICLE;
CLINICAL FEATURE;
DISEASE ACTIVITY;
FEMALE;
HUMAN;
HUMAN TISSUE;
MALE;
MALIGNANT FIBROUS HISTIOCYTOMA;
PARANEOPLASTIC SYNDROME;
PATHOLOGY;
PREOPERATIVE PERIOD;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN BLOOD LEVEL;
SOFT TISSUE SARCOMA;
SURVIVAL RATE;
ADULT;
AGED;
AGED, 80 AND OVER;
C-REACTIVE PROTEIN;
FEMALE;
HISTIOCYTOMA, BENIGN FIBROUS;
HUMANS;
MALE;
MIDDLE AGED;
MULTIVARIATE ANALYSIS;
NEOPLASM METASTASIS;
NEOPLASM RECURRENCE, LOCAL;
PARANEOPLASTIC SYNDROMES;
PROGNOSIS;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 0037052750
PISSN: 00207136
EISSN: None
Source Type: Journal
DOI: 10.1002/ijc.10343 Document Type: Article |
Times cited : (43)
|
References (22)
|